Abstract: A computer-implemented technique is described herein for defining and applying constraints that regulate a supervisee's interaction with applications. In one implementation, the technique provides a user interface presentation to a supervisor that lists a set of applications that run on plural application execution platforms. The user interface presentation also allows the supervisor to set platform-agnostic constraint information for any identified application. The platform-agnostic constraint information, once set for an application, constrains interaction by a supervisee with all versions of that same application. That is, the constraint information is said to be agnostic with respect to platform in the sense that it applies to a variety of application execution platforms that run the application. In one example, the platform-agnostic constraint information specifies a permitted amount of an activity that the supervisee is permitted to perform across all versions of an application.

Abstract: A computer-implemented technique is described herein for defining and applying constraints that regulate a supervisee's interaction with applications. In one implementation, the technique provides a user interface presentation to a supervisor that lists a set of applications that run on plural application execution platforms. The user interface presentation also allows the supervisor to set platform-agnostic constraint information for any identified application. The platform-agnostic constraint information, once set for an application, constrains interaction by a supervisee with all versions of that same application. That is, the constraint information is said to be agnostic with respect to platform in the sense that it applies to a variety of application execution platforms that run the application. In one example, the platform-agnostic constraint information specifies a permitted amount of an activity that the supervisee is permitted to perform across all versions of an application.

Abstract: A computer-implemented technique is described herein for defining and applying constraints that regulate a supervisee's interaction with applications. In one implementation, the technique provides a user interface presentation to a supervisor that lists a set of applications that run on plural application execution platforms. The user interface presentation also allows the supervisor to set platform-agnostic constraint information for any identified application. The platform-agnostic constraint information, once set for an application, constrains interaction by a supervisee with all versions of that same application. That is, the constraint information is said to be agnostic with respect to platform in the sense that it applies to a variety of application execution platforms that run the application. In one example, the platform-agnostic constraint information specifies a permitted amount of an activity that the supervisee is permitted to perform across all versions of an application.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.

Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.

Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Abstract: The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of forkhead box O1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding forkhead box O1A. Methods of using these compounds for modulation of forkhead box O1A expression and for treatment of diseases associated with expression of forkhead box O1A are provided, in particular, for methods of treating diabetes.

Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.

Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.

Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.